LOS ANGELES CAPITAL MANAGEMENT LLC - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.

Quarter-by-quarter ownership
LOS ANGELES CAPITAL MANAGEMENT LLC ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$325,987
-39.1%
12,132
-19.1%
0.00%
-50.0%
Q2 2023$534,900
+147.5%
15,000
+76.3%
0.00%
+100.0%
Q1 2023$216,154
-59.0%
8,510
-34.6%
0.00%
-66.7%
Q4 2022$527,645
+13.2%
13,009
-7.8%
0.00%
+50.0%
Q3 2022$466,000
+4.3%
14,109
+11.0%
0.00%0.0%
Q2 2022$447,000
+9.8%
12,708
+43.6%
0.00%0.0%
Q1 2022$407,000
-27.3%
8,847
+4.7%
0.00%0.0%
Q4 2021$560,000
+7.7%
8,453
+1.6%
0.00%0.0%
Q3 2021$520,000
-31.0%
8,323
-8.6%
0.00%
-33.3%
Q2 2021$754,000
-45.2%
9,104
-56.1%
0.00%
-50.0%
Q1 2021$1,375,000
-55.7%
20,731
-48.8%
0.01%
-53.8%
Q4 2020$3,104,000
+59.6%
40,456
-10.4%
0.01%
+44.4%
Q3 2020$1,945,000
-60.1%
45,166
-60.0%
0.01%
-60.9%
Q2 2020$4,880,000
+51.9%
112,993
+1.2%
0.02%
+15.0%
Q1 2020$3,213,000
-51.0%
111,670
+8.0%
0.02%
-39.4%
Q4 2019$6,557,000
+134.3%
103,370
+4.1%
0.03%
+120.0%
Q3 2019$2,798,000
+400.5%
99,305
+371.1%
0.02%
+400.0%
Q2 2019$559,000
+90.8%
21,080
+31.9%
0.00%
+50.0%
Q1 2019$293,00015,9800.00%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
WESTERN FINANCIAL Corp 820,264$54,392,00033.22%
Johnson & Johnson Innovation - JJDC, Inc. 3,260,869$216,228,00028.00%
L1 Capital Pty Ltd 296,024$19,629,0004.93%
Aquilo Capital Management, LLC 407,926$27,050,0004.89%
Evolutionary Tree Capital Management, LLC 72,948$4,837,0002.86%
ACUTA CAPITAL PARTNERS, LLC 108,000$7,161,0002.58%
First Light Asset Management, LLC 536,836$35,598,0002.36%
Parkman Healthcare Partners LLC 70,089$4,648,0001.08%
Hood River Capital Management LLC 357,082$23,678,0000.76%
Vanguard Capital Wealth Advisors 11,099$703,565,0000.60%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders